氟马西尼逆转雷米唑仑诱导的镇静：安全性、药代动力学和临床考虑的叙述性综述

摘要(中文译文)

瑞马唑仑是一种经羧酸酯酶-1（CES1）代谢的超短效苯二氮䓬类药物，可被氟马西尼特异性拮抗，从而实现丙泊酚镇静所不具备的主动逆转。然而，该逆转策略的安全性特征——包括再镇静风险、癫痫发作顾虑及特殊人群注意事项——仍未得到充分阐明。本叙述性综述综合了通过全面检索PubMed、Embase、Cochrane图书馆和Google Scholar（截至2026年2月）所识别的随机对照试验、荟萃分析、药代动力学-药效动力学建模研究及药物基因组学研究证据，以评估氟马西尼逆转在瑞马唑仑麻醉中的临床效用及安全性考量。近期荟萃分析表明，与丙泊酚相比，瑞马唑仑-氟马西尼可使苏醒加快约4分钟，并显著减少呼吸抑制（RR 0.41；95% CI 0.30-0.56）和低血压（RR 0.25；95% CI 0.12-0.52），但显著的异质性（I² = 96%）限制了合并估计值的精确性。再镇静发生率为2%-22%，取决于手术时长和结局定义，这种变异性主要反映的是手术场景的异质性和结局定义的不一致，而非药物基因组学因素。CES1的药物基因组学，尤其是G143E功能丧失多态性，是一个新兴领域，可能影响瑞马唑仑的代谢和逆转动力学。将外科数据库证据与FAERS分析中升高的药物警戒信号进行调和，提示急诊场景中存在适应证混杂；然而，GABA-A受体快速去占据所固有的神经生理学风险仍需持续警惕。苯磺酸瑞马唑仑制剂中的右旋糖酐40赋形剂禁用于严重右旋糖酐过敏患者，当血流动力学恶化对氟马西尼无反应时，临床医生应考虑非苯二氮䓬类病因。在新生儿中，CES1活性不成熟加之肾脏清除率降低，产生代谢物蓄积的理论风险，禁止在研究环境之外使用。本综述识别了关键证据缺口——包括需要标准化的再镇静定义、药代动力学-药效动力学模型的前瞻性验证以及儿科药代动力学数据——并为临床实践提供了基于证据的考量，同时强调需要系统综述方法和专家共识来制定正式的临床指南。

Abstract

Remimazolam, an ultra-short-acting benzodiazepine metabolized by carboxylesterase-1 (CES1), permits specific antagonism by flumazenil, enabling active reversal unavailable with propofol-based sedation. However, the safety profile of this reversal strategy-including re-sedation risk, seizure concerns, and special population considerations-remains incompletely characterized. This narrative review synthesizes evidence from randomized controlled trials, meta-analyses, pharmacokinetic-pharmacodynamic modeling studies, and pharmacogenomic research identified through comprehensive searches of PubMed, Embase, the Cochrane Library, and Google Scholar through February 2026 to evaluate the clinical utility and safety considerations of flumazenil reversal in remimazolam-based anesthesia. Recent meta-analyses demonstrate that remimazolam-flumazenil accelerates emergence by approximately 4 min versus propofol with significant reductions in respiratory depression (RR 0.41; 95% CI 0.30-0.56) and hypotension (RR 0.25; 95% CI 0.12-0.52), though substantial heterogeneity ( = 96%) limits pooled estimate precision. Re-sedation occurs in 2-22% of cases depending on procedural duration and outcome definitions, with this variability primarily reflecting heterogeneous procedural settings and inconsistent outcome definitions rather than pharmacogenomic factors. The pharmacogenomics of CES1, particularly the G143E loss-of-function polymorphism, represents an emerging area that may influence remimazolam metabolism and reversal kinetics. Reconciliation of surgical database evidence with elevated pharmacovigilance signals from FAERS analysis suggests confounding by indication in emergency settings; however, the intrinsic neurophysiological risks of rapid GABA-A receptor de-occupation warrant continued vigilance. The Dextran 40 excipient in remimazolam besylate formulations is contraindicated in patients with severe dextran hypersensitivity, and clinicians should consider non-benzodiazepine etiologies when hemodynamic deterioration does not respond to flumazenil. In neonates, immature CES1 activity combined with reduced renal clearance creates theoretical risk of metabolite accumulation, contraindicating use outside research settings. This review identifies critical evidence gaps-including the need for standardized re-sedation definitions, prospective validation of pharmacokinetic-pharmacodynamic models, and pediatric pharmacokinetic data-and provides evidence-based considerations for clinical practice while emphasizing the need for systematic review methodology and expert consensus to develop formal clinical guidelines.

如何引用

Frontiers in medicine 的其他文献

• SOFA 2.0评分对中暑患者住院死亡率的预测性能：一项多中心、数据驱动的亚表型研究
• 败血症患者红细胞分布宽度的三种不同轨迹及其与死亡率的显著关联：一项基于组的轨迹建模研究及其验证
• 构建和验证基于机器学习的慢性中耳炎患者术后并发症预测模型
• 印度西部间质性肺病患者TOLLIP和MUC5B单核苷酸多态性
• 阿美替尼作为辅助治疗用于II-IIIA期EGFR突变非小细胞肺癌的疗效和安全性：一项回顾性研究
• 放射学工作流程中的代理式人工智能：从图像解读到报告质量控制
• 雷米唑仑对剖宫产患者麻醉后寒战及相关临床反应的影响
• 粪菌移植用于心脏移植后消化道出血和穿孔的肠道康复：一例病例报告
• 骨肉瘤3D患者来源的培养物，用于测试基于基因组的个性化治疗方案：可行性研究
• 艾司他明联合QLB治疗老年体弱结直肠癌癌症手术患者的效果